Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company’s investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science.
Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent pro...
Salesforce (NYSE: CRM), the world’s #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN).
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co...
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16....
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2026.
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called “bad” cholesterol, number and the potential increased risk of heart attack or stroke.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck’s pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026.
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. IDVYNSO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers and lamivudine (3TC) or emtricitabine (FTC). Co-administration with these drugs may decrease the effectiveness of IDVYNSO. See additional selected safety information on the following pages. IDVYNSO (pronounced ihd-VIHN-soh) will be available in pharmacies after May 11.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated the triplet therapy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, plus WELIREG® (belzutifan), Merck’s first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. The study also evaluated MK-1308A, the coformulation of KEYTRUDA and quavonlimab, Merck’s investigational anti-CTLA-4 antibody, plus LENVIMA. Both combination regimens were compared to KEYTRUDA plus LENVIMA for these patients.
